Array BioPharma

Array BioPharma is a U.S.-based, clinical stage, pharmaceutical company that focuses on oncology medication. The company is a subsidiary of Pfizer.

Array BioPharma
Subsidiary of Pfizer
IndustryOncology
Medication
Founded1998 (1998)
FounderDrs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou
Headquarters
Boulder, Colorado
,
United States of America
Revenue$173.8 million (2018)
ParentPfizer
Websitewww.arraybiopharma.com

History

In 1998, the company was founded by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.[1]

In November 2000, the company became a public company via an initial public offering.[2]

In July 2013, the company partnered with Loxo Oncology to develop cancer drugs.[3]

In November 2015, the company signed a partnership with Laboratoires Pierre Fabre.[4]

In 2016, the company collaborated with Laboratoires Pierre Fabre for a phase three trial for a treatment of BRAF-mutant metastatic colorectal cancer.[5]

In May 2017, the company partnered with Ono Pharmaceutical to test the combination of binimetinib and encorafenib while retaining commercialization rights in the U.S. and other markets.[6]

In 2017, the company spun out one of its programs into a subsidiary called Yarra; the asset was a molecule called ARRY-797 that was in a Phase II trial for cardiomyopathy.[7]

In March 2018, Array sued AstraZeneca for breach of contract, saying that AstraZeneca owed it a 12% royalty on a portion of the $1.6 billion upfront payment that Merck had paid to AstraZeneca in a deal for selumetinib, which Array said it had licensed to AstraZeneca in 2003.[8]

In June 2018, the combination of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) was approved by the Food and Drug Administration for the treatment of people with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma.[9]

On September 20, 2018, the European Commission approved BRAFTOVI® in combination with MEKTOVI® for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation, as detected by a validated test.[10]

In July 2019, Pfizer acquired the company[11] for approximately $11 billion.[12][13]

References
  1. "Co-Founder Of Array BioPharma, Inc. To Lead New Korean Out-Sourcing Chemistry Company". BioSpace. Retrieved 2020-07-28.
  2. "Array IPO up 17%". CNN. November 17, 2000.
  3. "Loxo Oncology And Array BioPharma Announce License And Collaboration Agreement" (Press release). PR Newswire. July 10, 2013.
  4. "Innovation and Partnerships". Laboratoires Pierre Fabre.
  5. Hughes, Emily (June 6, 2016). "Merck, Pierre Fabre and Array BioPharma collaborate for cancer drug clinical trial". EPM Magazine.
  6. "Array BioPharma And Ono Pharmaceutical Co., Ltd. Announce A License, Development And Commercialization Partnership For Two Novel Oncology Compounds, Binimetinib And Encorafenib" (Press release). PR Newswire. May 31, 2017.
  7. Castle, Shay (December 26, 2017). "Boulder's Array BioPharma spins out subsidiary to develop rare-disease drugs". The Denver Post.
  8. Vogt, RJ (March 19, 2018). "AstraZeneca Owes $192M For Cancer Drug Rights, Rival Says". Law360.
  9. "FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations" (Press release). Food and Drug Administration. June 27, 2018.
  10. "Pierre Fabre Receives EU Approval for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in Adult Patients with Advanced BRAF-Mutant Melanoma" (Press release). Business Wire. September 20, 2018.
  11. "PFIZER COMPLETES ACQUISITION OF ARRAY BIOPHARMA" (Press release). Pfizer. July 30, 2019.
  12. "Array played with Pfizer's eagerness to land a deal on time—and got itself a better offer". FiercePharma. Retrieved 2020-07-29.
  13. "Pfizer acquires Array BioPharma, valued at $11.4 billion". Rappler. Retrieved 2020-07-29.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.